Funding & Deals
Sep 11, 2026 · 1 min read · 24,770 views
BridgeBio's oncology spinout sticks with SPAC to land on Nasdaq
L
Liam Turner
Editorial · Sep 11, 2026
BridgeBio Oncology Therapeutics will go public on Tuesday, marking a rare moment for the biotech field this year. But the new Nasdaq entrant won't be taking the traditional IPO route
← Previous
Max Gelman - Endpoints News
Next →
More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem
